Equities analysts expect that Arcturus Therapeutics Ltd (NASDAQ:ARCT) will post $3.73 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Arcturus Therapeutics’ earnings, with estimates ranging from $3.00 million to $4.46 million. Arcturus Therapeutics reported sales of $2.39 million in the same quarter last year, which indicates a positive year-over-year growth rate of 56.1%. The company is expected to issue its next earnings report on Monday, October 7th.

According to Zacks, analysts expect that Arcturus Therapeutics will report full year sales of $12.74 million for the current year, with estimates ranging from $6.80 million to $18.06 million. For the next year, analysts forecast that the firm will report sales of $14.44 million, with estimates ranging from $10.00 million to $18.88 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Arcturus Therapeutics.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.15). The business had revenue of $4.35 million during the quarter, compared to the consensus estimate of $3.47 million. Arcturus Therapeutics had a negative return on equity of 132.46% and a negative net margin of 124.59%.

Several equities analysts recently issued reports on ARCT shares. Zacks Investment Research upgraded shares of Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Tuesday. HC Wainwright set a $2.00 price objective on shares of POET Technologies and gave the company a “buy” rating in a research report on Friday, April 5th. Chardan Capital set a $18.00 target price on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research report on Thursday, June 20th. Finally, ValuEngine upgraded shares of United Overseas Bank from a “sell” rating to a “hold” rating in a research report on Monday, June 17th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Arcturus Therapeutics currently has an average rating of “Buy” and an average target price of $14.33.

ARCT traded up $0.26 during midday trading on Friday, reaching $9.36. The company’s stock had a trading volume of 4,418 shares, compared to its average volume of 96,254. The company has a market capitalization of $120.44 million, a price-to-earnings ratio of -4.33 and a beta of 2.30. The company has a debt-to-equity ratio of 2.43, a current ratio of 2.51 and a quick ratio of 2.51. Arcturus Therapeutics has a 1 year low of $4.11 and a 1 year high of $10.29. The company’s 50-day simple moving average is $8.16.

Large investors have recently made changes to their positions in the company. ARK Investment Management LLC raised its stake in Arcturus Therapeutics by 13.7% in the first quarter. ARK Investment Management LLC now owns 927,144 shares of the biotechnology company’s stock valued at $6,332,000 after buying an additional 111,968 shares during the period. Nikko Asset Management Americas Inc. bought a new stake in Arcturus Therapeutics during the 1st quarter valued at $438,000. Finally, Creative Planning purchased a new position in shares of Arcturus Therapeutics during the 1st quarter valued at $416,000. 11.15% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.

Featured Article: What is a Special Dividend?

Get a free copy of the Zacks research report on Arcturus Therapeutics (ARCT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.